サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1646778

クラウドベースの創薬プラットフォームの世界市場

Cloud-Based Drug Discovery Platforms

出版日
ページ情報
英文 303 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
クラウドベースの創薬プラットフォームの世界市場
出版日: 2025年01月31日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 303 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

クラウドベースの創薬プラットフォームの世界市場は2030年までに68億米ドルに達する見込み

2023年に26億米ドルと推定されるクラウドベースの創薬プラットフォームの世界市場は、分析期間2023-2030年にCAGR 14.3%で成長し、2030年には68億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである医薬品ベンダー・エンドユースは、CAGR 15.2％を記録し、分析期間終了時には30億米ドルに達すると予測されます。バイオベンダー・エンドユース分野の成長率は、分析期間中CAGR 12.8%と推定されます。

米国市場は9億3,720万米ドルと推定、中国はCAGR 15.9％で成長すると予測

米国のクラウドベースの創薬プラットフォーム市場は、2023年に9億3,720万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億4,590万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは15.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.9%と13.2%と予測されています。欧州では、ドイツがCAGR約14.2%で成長すると予測されています。

世界のクラウドベースの創薬プラットフォーム市場- 主要動向と促進要因のまとめ

クラウドベースの創薬プラットフォームは医療のブレークスルーを加速させる鍵か？

クラウドベースの創薬プラットフォームは製薬業界に急速な変革をもたらし、より迅速で、より効率的で、費用対効果の高い医薬品開発を可能にする、これまでにない機会を提供しています。従来、創薬は、物理的なインフラ、洗練された機器、人的資源への大規模な投資を必要とする困難なプロセスでした。しかし、クラウド・テクノロジーへのシフトは、製薬会社や研究機関がオンプレミスの大規模なインフラに投資することなく、計算生物学、人工知能、ビッグデータ解析のパワーを活用できるようにすることで、この状況を再構築しています。新興感染症や抗生物質耐性といったヘルスケアの課題が高まる中、イノベーションを世界的に推進していることが、この移行の大きな推進力となっています。クラウドベースのプラットフォームは、地域を超えた共同研究を可能にし、リアルタイムでのデータ、知識、ツールの交換を促進します。さらに、ゲノミクス、プロテオミクス、その他のソースから得られる生物学的データの複雑化により、従来のデータ処理方法は非効率的になっています。クラウドプラットフォームは、これらの大規模データセットの解析に必要な計算能力を提供し、潜在的な薬剤候補の同定を加速し、創薬プロセス全体を迅速化します。

クラウドベースのプラットフォームはどのように創薬に革命を起こしているのか？

クラウドベースの創薬プラットフォームは、主に膨大な量のデータ、コンピューティングリソース、人工知能ツールの統合を通じて、従来の手法よりも多くの利点を提供します。これらのプラットフォームがもたらす最も大きな影響のひとつは、ゲノム、化学ライブラリ、臨床試験、電子カルテから得られる膨大なデータセットを、従来の方法を用いた場合の数分の一の時間で解析できることです。クラウドプラットフォームはハイスループットスクリーニングを促進し、研究者は何千もの化合物と生物学的標的との相互作用を同時に評価することができます。これにより、さらなる調査に有望な候補を特定するまでの時間が短縮されます。クラウドベース・プラットフォームのもう一つの重要な側面は、研究者、製薬会社、学術機関の間で、地理的な場所に関係なくコラボレーションを促進する能力です。このように最先端のツールやリソースへのアクセスが民主化されることで、イノベーションへの障壁が取り除かれつつあります。さらに、クラウドプラットフォームは、医薬品候補の有効性、毒性、副作用を予測するAIや機械学習アルゴリズムを組み込むのに特に適しています。これにより、医薬品開発の初期段階での成功の可能性が高まるだけでなく、コストと時間のかかるin vitro試験やin vivo試験の必要性も減少します。

クラウドベースの創薬の成功を可能にするテクノロジーとは？

クラウドベースの創薬プラットフォームを推進する中核技術の進歩は、人工知能、機械学習、ビッグデータ解析の統合です。これらの技術により、製薬研究者は膨大なデータセットをふるいにかけ、手作業や従来の計算手法では困難または不可能であったパターンや関係を特定することができます。AIや機械学習モデルは、何百万もの既知の化学構造、生物学的相互作用、臨床結果からなるデータセットで訓練され、どの新規化合物が実行可能な医薬品候補として成功する可能性が最も高いかを予測できるようになっています。もうひとつの重要な技術的推進力は、創薬プロセスへの進出を始めている量子コンピューターの利用です。量子コンピューターは、複雑な分子構造をシミュレートし、薬が特定のタンパク質や遺伝子マーカーとどのように相互作用するかを、従来のコンピューターよりも高い精度で予測することができます。また、クラウドベースのプラットフォームは、安全なAPIを活用して検査情報管理システム（LIMS）、患者データベース、サードパーティツールと統合し、初期研究から臨床試験までのシームレスなワークフローを実現します。さらに、クラウドプラットフォームのスケーラビリティにより、研究者は、ハードウェアの追加購入に伴う法外なコストをかけることなく、必要なときにコンピューティングパワーを迅速に拡張することができます。この柔軟性は、発見の段階によって計算ニーズが劇的に変化するプロジェクトにとって極めて重要です。

クラウドベースの創薬プラットフォーム市場の主な成長促進要因は？

クラウドベースの創薬プラットフォーム市場の成長の原動力はいくつかの要因であり、それぞれが製薬研究開発の状況の変化を浮き彫りにしています。第一に、生物学的データの複雑化と量の増加は、従来のデータ処理手法の能力を凌駕しています。クラウドプラットフォームは、膨大なデータセットを迅速かつ効率的に処理・解析するために必要な計算能力を提供し、わずかな時間で医薬品候補を特定することを可能にします。AIや機械学習技術の採用も重要な推進力となっています。これらのツールにより、研究者は創薬プロセスの早い段階で、医薬品の有効性、安全性、副作用について、より多くの情報に基づいた予測を行うことができるからです。これにより、医薬品開発に関連する時間とコストの両方が削減されるため、業務の合理化を目指す製薬企業にとっては特に魅力的なものとなります。さらに、個別化医療のトレンドがクラウドプラットフォームの利用を後押ししています。これらのシステムは、ゲノムおよびプロテオミクスデータを統合して、個々の患者に合った治療を特定することができるからです。クラウドプラットフォームの協調的な性質も、重要な成長要因です。研究者、製薬会社、学術機関の間でリアルタイムのデータ共有を可能にすることで、クラウドベースのプラットフォームはイノベーションを加速し、努力の重複を減らします。さらに、従量課金モデルで運用されるクラウドプラットフォームが提供する経済的柔軟性により、中小企業や新興企業でもハイエンドの計算リソースにアクセスすることが可能になり、競合の多い創薬市場での競争の土俵が平準化されます。

セグメント

サービスタイプ（PaaS（Platform as a Service）、SaaS（Software as a Service）、IaaS（Infrastructure as a Service））、エンドユーザー（製薬ベンダー・エンドユーザー、バイオテクノロジー・ベンダー・エンドユーザー、医薬品開発業務受託機関エンドユーザー、その他エンドユーザー）

調査対象企業の例（全59件）

  • Accenture PLC
  • BioXcel LLC
  • Cloud Pharmaceuticals, Inc.
  • Conifer Point Pharmaceuticals
  • Dassault Systemes SE
  • GenScript Biotech Corporation
  • Merative
  • Selvita S.A.
  • Tata Consultancy Services Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP11099

Global Cloud-Based Drug Discovery Platforms Market to Reach US$6.8 Billion by 2030

The global market for Cloud-Based Drug Discovery Platforms estimated at US$2.6 Billion in the year 2023, is expected to reach US$6.8 Billion by 2030, growing at a CAGR of 14.3% over the analysis period 2023-2030. Pharmaceutical Vendors End-Use, one of the segments analyzed in the report, is expected to record a 15.2% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Biotech Vendors End-Use segment is estimated at 12.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$937.2 Million While China is Forecast to Grow at 15.9% CAGR

The Cloud-Based Drug Discovery Platforms market in the U.S. is estimated at US$937.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$745.9 Million by the year 2030 trailing a CAGR of 15.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 13.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.2% CAGR.

Global Cloud-Based Drug Discovery Platforms Market - Key Trends and Drivers Summarized

Are Cloud-Based Drug Discovery Platforms the Key to Faster Breakthroughs in Medicine?

Cloud-based drug discovery platforms are rapidly transforming the pharmaceutical industry, providing unprecedented opportunities for faster, more efficient, and cost-effective drug development. Traditionally, drug discovery has been an arduous process requiring massive investments in physical infrastructure, sophisticated equipment, and human resources. The shift toward cloud technology, however, is reshaping this landscape by allowing pharmaceutical companies and research institutions to harness the power of computational biology, artificial intelligence, and big data analytics without needing to invest in extensive on-premise infrastructure. The global push for innovation in the face of rising healthcare challenges, such as emerging diseases and antibiotic resistance, is a major driver for this transition. Cloud-based platforms enable collaborative research across geographies, facilitating the exchange of data, knowledge, and tools in real time. Moreover, the increasing complexity of biological data from genomics, proteomics, and other sources has made traditional data processing methods inefficient. Cloud platforms provide the computational power needed to analyze these large datasets, accelerating the identification of potential drug candidates and expediting the entire drug discovery process.

How Are Cloud-Based Platforms Revolutionizing Drug Discovery?

Cloud-based drug discovery platforms offer numerous advantages over traditional methods, primarily through the integration of vast amounts of data, computing resources, and artificial intelligence tools. One of the most significant impacts of these platforms is the ability to analyze massive datasets from genomics, chemical libraries, clinical trials, and electronic health records in a fraction of the time it would take using conventional methods. Cloud platforms facilitate high-throughput screening, allowing researchers to evaluate the interactions between thousands of compounds and biological targets simultaneously. This reduces the time it takes to identify promising candidates for further investigation. Another critical aspect of cloud-based platforms is their ability to foster collaboration between researchers, pharmaceutical companies, and academic institutions, regardless of their geographic location. This democratization of access to cutting-edge tools and resources is breaking down barriers to innovation. Furthermore, cloud platforms are particularly well-suited for incorporating AI and machine learning algorithms that predict the efficacy, toxicity, and side effects of drug candidates. This not only improves the likelihood of success in the early stages of drug development but also reduces the need for costly and time-consuming in vitro and in vivo testing.

How Does Technology Enable the Success of Cloud-Based Drug Discovery?

The core technological advancements driving cloud-based drug discovery platforms are the integration of artificial intelligence, machine learning, and big data analytics. These technologies enable pharmaceutical researchers to sift through massive datasets, identifying patterns and relationships that would otherwise be difficult or impossible to discern using manual or traditional computational methods. AI and machine learning models are being trained on datasets comprising millions of known chemical structures, biological interactions, and clinical outcomes, enabling them to predict which new compounds are most likely to succeed in becoming viable drug candidates. Another key technological driver is the use of quantum computing, which is beginning to make inroads into the drug discovery process. Quantum computers can simulate complex molecular structures and predict how drugs will interact with specific proteins or genetic markers with greater precision than traditional computers. Cloud-based platforms also leverage secure APIs to integrate with laboratory information management systems (LIMS), patient databases, and third-party tools, creating a seamless workflow from initial research to clinical trials. Furthermore, the scalability of cloud platforms allows researchers to quickly expand their computing power when needed, without the prohibitive costs associated with purchasing additional hardware. This flexibility is crucial for projects where computational needs can vary dramatically depending on the stage of discovery.

What Are the Key Growth Drivers in the Cloud-Based Drug Discovery Platforms Market?

The growth in the cloud-based drug discovery platform market is driven by several factors, each underscoring the changing landscape of pharmaceutical research and development. First, the increasing complexity and volume of biological data have outstripped the capabilities of traditional data processing methods. Cloud platforms provide the necessary computational power to process and analyze vast datasets quickly and efficiently, making it possible to identify drug candidates in a fraction of the time. The adoption of AI and machine learning technologies is another key driver, as these tools allow researchers to make more informed predictions about drug efficacy, safety, and side effects at earlier stages of the discovery process. This reduces both the time and cost associated with drug development, making it particularly attractive to pharmaceutical companies looking to streamline operations. Additionally, the trend toward personalized medicine is propelling the use of cloud platforms, as these systems can integrate genomic and proteomic data to identify treatments tailored to individual patients. The collaborative nature of cloud platforms is also a critical growth factor. By enabling real-time data sharing between researchers, pharmaceutical companies, and academic institutions, cloud-based platforms accelerate innovation and reduce duplication of efforts. Furthermore, the financial flexibility offered by cloud platforms, which operate on a pay-as-you-go model, allows even smaller companies and startups to access high-end computational resources, leveling the playing field in the competitive drug discovery market.

SCOPE OF STUDY:

The report analyzes the Cloud-Based Drug Discovery Platforms market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service Type (PaaS (Platform as a Service), SaaS (Software as a Service), IaaS (Infrastructure as a Service)); End-Use (Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 59 Featured) -

  • Accenture PLC
  • BioXcel LLC
  • Cloud Pharmaceuticals, Inc.
  • Conifer Point Pharmaceuticals
  • Dassault Systemes SE
  • GenScript Biotech Corporation
  • Merative
  • Selvita S.A.
  • Tata Consultancy Services Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Cloud-based Drug Discovery Platforms: Revolutionizing Pharmaceutical Research
    • Drug Discovery Evolves with Cloud-Based Platforms
    • Economic Frontiers: Trends, Trials & Transformations
    • EXHIBIT 1: In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
    • EXHIBIT 2: All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
    • EXHIBIT 3: With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
    • Competitive Scenario
    • Existing Players & Pioneering Start-Ups Shaping Dynamics of Cloud Based Drug Discovery Platform Market
    • EXHIBIT 4: Cloud-Based Drug Discovery Platforms - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Market Overview and Prospects
    • Global Cloud-Based Drug Discovery Platforms Market Discovers New Growth Horizons
    • Pharmaceutical Companies: Leading End-User Segment of Global Market
    • North America Rules Global Cloud-Based Drug Discovery Platforms Market
    • Europe to Exhibit Consistent Growth
    • Asia-Pacific Region to Enjoy Healthy Growth
    • Global Cloud Based Drug Discovery Platform Market on a High with Pulsating Drivers
    • Rising Costs & Complexity of Drug Discovery Process
    • Massive Investments in Drug Discovery R&D
    • Intriguing Perks of Cloud-based Platforms
    • Advances Favoring Cloud-Based Drug Discovery Platforms
    • Influx of Advanced Solutions
    • Recent Market Activity
    • Influencer/Product/Technology Insights
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Cloud-Based Drug Discovery Platforms: The Pill of Choice to Expedite Drug Discovery
    • EXHIBIT 5: Increase in R&D Costs of a New Approved Drug (1980s-2020s)
    • Increasing R&D Investments and the Rising Demand for Cloud-Based Drug Discovery Platforms
    • EXHIBIT 6: Global Pharmaceutical R&D Spending in US$ Billion (2018-2026P)
    • The Role of Cloud-Based Platforms in Reducing Drug Costs
    • EXHIBIT 7: Global Prescription Drug Sales (In US$ Trillion) for the Years 2019, 2020, 2021 & 2022
    • Rise in Clinical Trials Powers Growth of Cloud-based Drug Discovery Platforms
    • EXHIBIT 8: Total Number of Registered Clinical Studies in'000s Worldwide (2012-2024)
    • Adoption of Advanced Technologies in Cloud-Based Drug Discovery Propels Market Growth
    • Adoption of Advanced Technologies in Cloud-Based Drug Discovery Propels Market Growth
    • The Transformative Impact of AI and Machine Learning in Drug Discovery
    • The Advantages of Cloud Adoption for Pharmaceutical Manufacturers
    • Precision Medicine Meets Artificial Intelligence: Revolutionizing Drug Discovery for a Personalized Future
    • Optimizing Cloud Costs for the Pharmaceutical Industry with Data Platforms
    • The Role of Hybrid Cloud Platforms in Advancing Drug Discovery and Life Sciences
    • Cloud Security Challenges in Cloud-Based Drug Discovery for the Pharmaceutical Industry
    • Enhancing Collaborative Research in Cloud-Based Drug Discovery with AI and Cloud Technologies
    • The Rising Adoption of Cloud-Based Drug Discovery Platforms in Emerging Markets
    • In-Silico Drug Discovery Gears Up to Eureka Moment with Cloud-based Platforms
    • Demand for Cloud-based Drug Discovery Platforms from CROs Set to Increase Rapidly
    • EXHIBIT 9: Global Contract Research Outsourcing Market Revenues (US$ Million) by Geographic Region/Country for 2020 and 2027
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cloud-Based Drug Discovery Platforms Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cloud-Based Drug Discovery Platforms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cloud-Based Drug Discovery Platforms by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pharmaceutical Vendors End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pharmaceutical Vendors End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Pharmaceutical Vendors End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biotech Vendors End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biotech Vendors End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biotech Vendors End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cloud-Based Drug Discovery Platforms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • Market Analytics
    • TABLE 17: USA Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • TABLE 26: China Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Cloud-Based Drug Discovery Platforms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • Market Analytics
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Cloud-Based Drug Discovery Platforms by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Cloud-Based Drug Discovery Platforms by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • TABLE 35: France Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • TABLE 44: UK Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cloud-Based Drug Discovery Platforms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • Market Analytics
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of World Historic Review for Cloud-Based Drug Discovery Platforms by End-Use - Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of World 16-Year Perspective for Cloud-Based Drug Discovery Platforms by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical Vendors End-Use, Biotech Vendors End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION